Breaking News Instant updates and real-time market news.

CASA

Casa Systems

$15.02

-0.03 (-0.20%)

, SCHW

Charles Schwab

$44.42

0.25 (0.57%)

10:16
11/30/18
11/30
10:16
11/30/18
10:16

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Casa Systems (CASA) initiated with a Buy at Needham. 2. Charles Schwab (SCHW) and E-Trade (ETFC) were initiated with a Buy at Goldman Sachs. 3. Forty Seven (FTSV) initiated with a Buy at H.C. Wainwright. 4. Akoustis (AKTS) initiated with a Buy at Lake Street. 5. Everi Holdings (EVRI) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

CASA

Casa Systems

$15.02

-0.03 (-0.20%)

SCHW

Charles Schwab

$44.42

0.25 (0.57%)

ETFC

E-Trade

$51.88

0.42 (0.82%)

FTSV

Forty Seven

$18.88

1.27 (7.21%)

AKTS

Akoustis

$4.78

-0.13 (-2.65%)

EVRI

Everi Holdings

$6.82

0.3 (4.60%)

  • 01

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 11

    Dec

  • 12

    Dec

CASA Casa Systems
$15.02

-0.03 (-0.20%)

10/22/18
STFL
10/22/18
INITIATION
Target $18
STFL
Buy
Casa Systems resumed with a Buy at Stifel
Stifel analyst John Marchetti resumed Casa Systems with a Buy rating and a price target of $18, saying the company is "well positioned to benefit from ongoing cable operator infrastructure and capacity upgrades in the near term". The analyst adds that Casa System is also "positioning itself to capitalize on technology shifts toward distributed access architectures and mobile network convergence over the long-term". Marchetti sees the stock trading at an "attractive valuation" as his price target represents a 4.1-times enterprise value to expected sales multiple.
08/24/18
LOOP
08/24/18
UPGRADE
Target $18
LOOP
Buy
Casa Systems upgraded to Buy from Hold at Loop Capital
Loop Capital analyst James Kisner upgraded Casa Systems to Buy and raised his price target for the shares to $18 from $12. Recent softness in the business is chiefly a function of customer concentration, Kisner tells investors in a research note titled "The House of the Rising Sun." He believes the "sun will rise again" for Casa as cable operators continue to invest in their networks to accommodate higher speeds and data traffic growth. Consensus estimates for the second half of 2018 are achievable even if Casa's two biggest customers are down 30% year-over-year, Kisner contends.
08/15/18
LOOP
08/15/18
NO CHANGE
Target $12
LOOP
Hold
Casa Systems price target lowered to $12 from $16 at Loop Capital
Loop Capital analyst James Kisner lowered his price target on Casa Systems to $12 and kept his Hold rating after its Q2 earnings miss and lowered expectations for FY18. Kisner notes the earnings miss was driven by a push-out of orders and revenue recognition, and lowered guidance was a victim to a "more deliberate pace of infrastructure deployments by cable operators". The analyst states that he is keeping a positive view of the cable access market in the long term, but adds that the last quarter highlighted Casa Systems' risks around customer concentration and "lumpy order patterns".
11/29/18
NEED
11/29/18
INITIATION
Target $19
NEED
Buy
Casa Systems initiated with a Buy at Needham
Needham analyst Richard Valera started Casa Systems with a Buy rating and $19 price target. The analyst believes the company is positioned for sustained double-digit sales growth with continued 30%-plus operating margins.
SCHW Charles Schwab
$44.42

0.25 (0.57%)

11/30/18
GSCO
11/30/18
INITIATION
GSCO
Buy
Charles Schwab initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Will Nance initiated coverage of the Online Brokers with an Attractive coverage view, stating that for the group on the whole he believes cyclical factors will drive fundamentals and valuation in the near term despite organic growth and pricing concerns. He set a Buy rating on Charles Schwab (SCHW), stating that it along with E-Trade (ETFC) screens as the most defensive. He notes that his 2019 and 2020 estimates for Schwab are 2% and 8%, respectively, above Factset consensus.
11/26/18
SBSH
11/26/18
UPGRADE
Target $45
SBSH
Neutral
Charles Schwab upgraded to Neutral from Sell at Citi
Citi analyst William Katz upgraded Charles Schwab to Neutral while lowering his price target for the shares to $45 from $46.
11/30/18
GSCO
11/30/18
INITIATION
Target $64
GSCO
Buy
E-Trade initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Will Nance initiated coverage of the Online Brokers with an Attractive coverage view, stating that for the group on the whole he believes cyclical factors will drive fundamentals and valuation in the near term despite organic growth and pricing concerns. He set a Buy rating on E-Trade (ETFC), stating that it along with Charles Schwab (SCHW) screens as the most defensive. He notes that his 2019 and 2020 estimates for E-Trade are 5% and 9%, respectively, above Factset consensus. Nance set a $64 price target on E-Trade shares and a $55 price target on Charles Schwab.
11/26/18
SBSH
11/26/18
UPGRADE
Target $45
SBSH
Neutral
Citi upgrades Schwab to Neutral on more balanced risk/reward
Citi analyst William Katz upgraded Charles Schwab to Neutral from Sell while lowering his price target for the shares to $45 from $46. After examining whether retail brokers can prove defensive against higher volatility and/or a more decisive market downturn, the analyst sees a more balanced risk/reward at current share levels.
ETFC E-Trade
$51.88

0.42 (0.82%)

10/30/18
10/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. LabCorp (LH) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg saying the company is faced with pressure from "lower lab testing payment rates mandated by the Protecting Access to Medicaid Act of 2014" along with business disruptions and the impact of acquisitions which resulted in lowers margins for the quarter. 2. E-Trade (ETFC) downgraded to Outperform from Strong Buy at Raymond James with analyst Patrick O'Shaughnessy saying the recent board decision not to sell the business and remain a standalone company takes a sales scenario off the table. The analyst remains positive on shares ans believes there is plenty of upside as management executes on its operating plan. 3. Southwest (LUV) downgraded to Underweight from Neutral at JPMorgan while United Continental (UAL) and Spirit Airlines (SAVE) downgraded to Neutral from Overweight. 4. Flex (FLEX) downgraded to Hold from Buy at Argus with analyst Jim Kelleher citing the expected impact from the "shutdown of Mexican operations with key customer Nike (NKE), which he expects to be fully unwound," as well as the retirement of the company CEO Mike McNamara who had presided over the company's business expansion. 5. Elevate Credit (ELVT) downgraded to Market Perform from Outperform at JMP Securities and William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/18
WOLF
11/02/18
UPGRADE
WOLF
Outperform
E-Trade upgraded to Outperform from Peer Perform at Wolfe Research
FTSV Forty Seven
$18.88

1.27 (7.21%)

07/23/18
FBCO
07/23/18
INITIATION
Target $24
FBCO
Outperform
Forty Seven initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started Forty Seven with an Outperform rating and $24 price target as he believes the stock offers a promising opportunity for investors to participate in the long-term potential of this class, with promising efficacy in NHL offering a valuation base, and substantial upside potential as its 5F9 efficacy data matures in other monotherapy and combination settings.
07/23/18
MSCO
07/23/18
INITIATION
Target $25
MSCO
Overweight
Forty Seven initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison initiated Forty Seven with an Overweight rating and $25 price target, stating that the company has a significant lead in developing anti-CD47 antibodies, which he believes offer broad applicability in cancer. Forty Seven has multiple mature clinical datasets, potentially placing it "years ahead" of competitors, Harrison tells investors.
10/09/18
FBCO
10/09/18
NO CHANGE
FBCO
Outperform
Forty Seven selloff on Celgene trial ending seems premature, says Credit Suisse
After Celgene (CELG) disclosed the termination of its trial for CC-90002, an IgG4 construct that targets CD47, in acute myeloid leukemia and myelodysplastic syndrome patients, Credit Suisse analyst Martin Auster said the associated selloff in shares of Forty Seven (FTSV) seems premature to him. He does not believe the discontinuation in AML/MDS has a negative read-through to Forty Seven's 5F9 profile to date or its development in other indications, Auster tells investors. The analyst, who keeps an Outperform rating on Forty Seven shares, still sees promising efficacy in NHL providing a strong valuation base with substantial upside potential offered as 5F9 efficacy data matures.
11/30/18
HCWC
11/30/18
INITIATION
Target $21
HCWC
Buy
Forty Seven initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Forty Seven with a Buy rating and $21 price target. The company's lead product, 5F9, is an anti-CD47 antibody that triggers macrophages to eat cancer cells by blocking the CD47-SIRPalpha pathway, which is frequently exploited by cancer cells for immune evasion, Ramakanth tells investors in a research note. He believes data suggest that 5F9 is synergistic with existing immunotherapies by making the tumor microenvironment less tumorigenic. If successful, 5F9 could become an important next-generation CPI to enter the cancer immunotherapy market, which is expected to grow to $43B by 2022, says the analyst.
AKTS Akoustis
$4.78

-0.13 (-2.65%)

10/10/18
PIPR
10/10/18
INITIATION
Target $10
PIPR
Overweight
Akoustis initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar started Akoustis Technologies with an Overweight rating and $10 price target. The analyst believes the company is well positioned to participate in the upcoming 5G cycle with its BAW filter portfolio. Akoustis's single crystal BAW filters offer several technological benefits over the current market offerings, Kumar tells investors in a research note.
11/01/18
LOOP
11/01/18
NO CHANGE
LOOP
Akoustis price target lowered to $11 from $15 at Loop Capital
Loop Capital analyst Cody Acree reiterated a Buy rating on Akoustis Technologies but lowered his price target on shares to $11 from $15. Acree noted that the company's "pullback since its recent financing provides it with the resources to accelerate its product development and capacity expansion efforts, and help its customers become more confident in its ability to reliably manufacture in high volumes." However, despite the reiterated Buy rating, the analyst lowered his price target due to multiple contractions across most of the semi group.
11/30/18
LSCM
11/30/18
INITIATION
Target $10
LSCM
Buy
Akoustis initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started Akoustis Technologies with a Buy rating and $10 price target. The company's "differentiated" products can help it gain share in the $5.4B bulk acoustic wave radio frequency filter market, Schmidt tells investors in a research note. He says Akoustis' expanding engagement pipeline will start to flow to profits in a "meaningful way" in the coming years.
09/24/18
LOOP
09/24/18
NO CHANGE
Target $15
LOOP
Buy
Akoustis on track to meet its targets, says Loop Capital
Loop Capital analyst Cody Acree kept his Buy rating and $15 price target on Akoustis after meeting with its management, saying the discussions added to his confidence of the company's ability to meet its WiFi, Radar, Infrastructure and Citizen Band Radio market targets. The analyst estimates that given its current headcount and a newly purchased fab in Canandaigua, New York, the company has the capacity to generate up to $200M in annual revenue.
EVRI Everi Holdings
$6.82

0.3 (4.60%)

11/30/18
RAJA
11/30/18
INITIATION
Target $11
RAJA
Strong Buy
Everi Holdings initiated with a Strong Buy at Raymond James
Raymond James initiated Everi Holdings with a Strong Buy and $11 price target.
11/16/18
JEFF
11/16/18
NO CHANGE
JEFF
Jefferies sees long-term investment opportunities in Gaming
The "profound weakness" in Gaming stocks has created dislocation which presents long-term investment opportunities, Jefferies analyst David Katz tells investors in a research note titled "'Buy On Weakness' Is Not Enough." The analyst says his "broad view" of asset value, leadership execution and capital structure risk lead to him focus on his top picks, Eldorado Resorts (ERI) and International Game Technology (IGT). He also has Buy ratings on Boyd Gaming (BYD), PlayAGS (AGS) and Everi Holdings (EVRI).
10/11/18
JEFF
10/11/18
NO CHANGE
JEFF
International Game, Everi pullbacks bring buying opportunity, says Jefferies
After attending the Global Gaming Expo, Jefferies analyst David Katz believes "broadly stronger" product offerings should be positive for Gaming stocks. The recent weakness in shares of International Game Technology (IGT) and Everi Holdings (EVRI), who both have "strong prospects," present buying opportunities, Katz tells investors in research note. He also believes PlayAGS' (AGS) relative outperformance is justified as its "growth opportunities warrant the premium multiple." Further, the analyst thinks Scientific Games (SGMS) has been overly pressured by a series of negative catalysts, "all of which should stabilize in time." The company's products "are too good for the shares' decline not to correct," Katz contends.
09/13/18
STFL
09/13/18
INITIATION
Target $13
STFL
Buy
Everi Holdings resumed with a Buy at Stifel
Stifel analyst Brad Boyer resumed coverage of Everi Holdings with a Buy rating and $13 price target. The company's current segment-level valuation "reflects a significant discount" when compared to prevailing public market multiples within the Gaming Equipment and Payments sectors, Boyer tells investors in a research note. He sees several potential catalysts that could narrow the valuation gap, including Everi's analyst day and the upcoming Global Gaming Expo. The analyst views the stock as a "one of the most compelling return opportunities for value investors of all varieties."

TODAY'S FREE FLY STORIES

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.